Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas. Its clinical development services include medical affairs, clinical trial management, feasibility and start-up study, clinical monitoring, global regulatory affairs, medical writing, biometrics, pharmacovigilance, core laboratory, and quality assurance. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Phone513-579-9911
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$436.15 million
Profitability
Miscellaneous
Employees2,500
OptionableOptionable
Medpace (NASDAQ:MEDP) Frequently Asked Questions
What is Medpace's stock symbol?
Medpace trades on the NASDAQ under the ticker symbol "MEDP."
How were Medpace's earnings last quarter?
Medpace Holdings Inc (NASDAQ:MEDP) released its quarterly earnings data on Thursday, November, 1st. The company reported $0.67 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.63 by $0.04. The business earned $179 million during the quarter, compared to analyst estimates of $175.07 million. Medpace had a return on equity of 15.86% and a net margin of 10.84%. The business's revenue for the quarter was up 44.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.40 EPS. View Medpace's Earnings History.
When is Medpace's next earnings date?
What guidance has Medpace issued on next quarter's earnings?
Medpace updated its FY18 earnings guidance on Monday, October, 29th. The company provided EPS guidance of $2.76-2.82 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.48. Medpace also updated its FY 2018 guidance to $2.76-2.82 EPS.
What price target have analysts set for MEDP?
7 analysts have issued twelve-month target prices for Medpace's stock. Their forecasts range from $35.00 to $63.00. On average, they expect Medpace's stock price to reach $42.8333 in the next twelve months. This suggests that the stock has a possible downside of 30.2%. View Analyst Price Targets for Medpace.
What is the consensus analysts' recommendation for Medpace?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Medpace.
Has Medpace been receiving favorable news coverage?
News articles about MEDP stock have been trending very positive on Tuesday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Medpace earned a coverage optimism score of 3.2 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Are investors shorting Medpace?
Medpace saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,286,982 shares, an increase of 63.3% from the December 14th total of 1,400,643 shares. Based on an average daily volume of 1,303,229 shares, the short-interest ratio is presently 1.8 days. Currently, 8.5% of the company's stock are short sold. View Medpace's Current Options Chain.
Who are some of Medpace's key competitors?
Some companies that are related to Medpace include Icon (ICLR), Exelixis (EXEL), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), BTG (BTGGF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), Senomyx (SNMX), Dyadic International (DYAI), BIOQUAL (BIOQ) and HedgePath Pharmaceuticals (HPPI).
Who are Medpace's key executives?
Medpace's management team includes the folowing people:
- Dr. August James Troendle, Chairman, Pres & CEO (Age 62)
- Mr. Jesse J. Geiger, CFO & Chief Operating Officer of Laboratory Operations (Age 44)
- Ms. Susan E. Burwig, Exec. VP of Operations (Age 55)
- Mr. Stephen P. Ewald, Gen. Counsel & Corp. Sec. (Age 49)
- Mr. Todd Meyers, VP of Bus. Devel. & Marketing
When did Medpace IPO?
(MEDP) raised $150 million in an initial public offering (IPO) on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.
Who are Medpace's major shareholders?
Medpace's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.17%), Bowling Portfolio Management LLC (0.08%), Campbell Newman Asset Management Inc. (0.03%), Navellier & Associates Inc (0.01%), Virtu Financial LLC (0.01%) and State of Alaska Department of Revenue (0.00%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Institutional Ownership Trends for Medpace.
Which major investors are selling Medpace stock?
MEDP stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC and Virtu Financial LLC. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Medpace Limited Partnership. View Insider Buying and Selling for Medpace.
Which major investors are buying Medpace stock?
MEDP stock was acquired by a variety of institutional investors in the last quarter, including Scout Investments Inc., Navellier & Associates Inc, State of Alaska Department of Revenue and Campbell Newman Asset Management Inc.. View Insider Buying and Selling for Medpace.
How do I buy shares of Medpace?
Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Medpace's stock price today?
One share of MEDP stock can currently be purchased for approximately $61.36.
How big of a company is Medpace?
Medpace has a market capitalization of $2.18 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.
What is Medpace's official website?
How can I contact Medpace?
Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]
MarketBeat Community Rating for Medpace (NASDAQ MEDP)
MarketBeat's community ratings are surveys of what our community members think about Medpace and other stocks. Vote "Outperform" if you believe MEDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
